Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034773 · ClinicalTrials.gov registry record · Phase 1
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
A Phase 1 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02034773 is a Phase 1 study that has completed, run by Celgene Corporation. The registered enrollment target is 64 participants.
The verdict
NCT02034773, a Phase 1 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
Interventions
- DRUG Placebo
- DRUG CC-220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02034773
The ClinicalTrials.gov registry entry for NCT02034773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02034773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02034773 about?
NCT02034773 is a clinical study titled "3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule". To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
What is the current status of trial NCT02034773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT02034773?
The interventions under investigation include: Placebo (DRUG), CC-220 (DRUG).
Who is sponsoring clinical trial NCT02034773?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.